For research use only. Not for therapeutic Use.
PHI-101(CAT: I040588) is an orally active, next-generation FLT3 inhibitor designed to overcome resistance associated with relapsed or refractory acute myeloid leukemia (AML). It exhibits potent inhibitory activity against FLT3 single mutations, including internal tandem duplication (ITD) and tyrosine kinase domain (TKD) variants, as well as clinically relevant double (ITD/D835Y, ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 effectively blocks mutant FLT3 signaling pathways that drive leukemic proliferation and survival, making it a valuable compound for studying resistance mechanisms and targeted therapy development in AML. Its broad mutation coverage supports its utility in advanced preclinical leukemia models and resistance profiling research.
| CAS Number | 2127107-15-5 |
| Synonyms | 3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide |
| Molecular Formula | C19H19FN4O2S |
| Purity | ≥95% |
| IUPAC Name | 3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide |
| InChI | InChI=1S/C19H19FN4O2S/c20-13-4-1-3-12(9-13)6-7-15-10-16(24-19(21)26)17(27-15)18(25)23-14-5-2-8-22-11-14/h1,3-4,9-10,14,22H,2,5,8,11H2,(H,23,25)(H3,21,24,26)/t14-/m0/s1 |
| InChIKey | ULVAGWVTXBTFRN-AWEZNQCLSA-N |
| SMILES | C1CC(CNC1)NC(=O)C2=C(C=C(S2)C#CC3=CC(=CC=C3)F)NC(=O)N |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
